title: Cytotoxic T lymphocyte precursor frequency as a predictor of acute graft-versus-host disease in bone marrow transplantation from HLA-identical siblings.
abstract: The measurement of precursor frequencies of donor anti-recipient cytotoxic T lymphocytes (CTL-p) has been shown to predict the incidence and the severity of acute graft-versus-host disease (aGVHD) in unrelated donor bone marrow transplantation (BMT). In HLA-identical sibling BMT, where aGVHD is most likely caused by minor histocompatibility antigen mismatches, this assay did not appear to be sensitive enough to provide similar predictive information. In this study, the CTL-p frequencies and the incidence and severity of aGVHD in 51 onco-hematological patients transplanted from HLA-identical siblings were compared. Sibling donors were selected on the basis of HLA identity using serological typing for HLA-A, B, C antigens, whereas HLA-DRB was tested by molecular analysis. Sibling identity was also confirmed by DNA heteroduplex analyses. Fifteen out of 21 (71%) patients with high precursor frequency (>1:100 x 10(3)) and 12 out of 30 (40%) with low precursor frequency (<1:100 x 10(3)) experienced clinically significant (II-IV) aGVHD. A significant correlation (P = 0.04) between CTL-p frequency and severe aGVHD was demonstrated. Moreover there was a positive trend for a high frequency response according to an increasing grade of aGVHD, which was statistically significant (P = 0.04). In our experience the CTL-p assay is a helpful predictive test for aGVHD in HLA-identical sibling BMT, indicating high risk patients possibly requiring additional prophylaxis.
authors.affiliation: Department of Genetics, Biology and Biochemistry, University of Turin, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Affaticati
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: S
authors.initials: S
authors.lastname: Roggero
authors.forename: F
authors.initials: F
authors.lastname: Marmont
authors.forename: M
authors.initials: M
authors.lastname: Falda
authors.forename: A M
authors.initials: AM
authors.lastname: Dall'Omo
authors.forename: A
authors.initials: A
authors.lastname: Busca
authors.forename: C
authors.initials: C
authors.lastname: Ceretto
authors.forename: L
authors.initials: L
authors.lastname: Praticò
authors.forename: M
authors.initials: M
authors.lastname: Berrino
authors.forename: E S
authors.initials: ES
authors.lastname: Curtoni
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006650:Histocompatibility Testing; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009679:Nuclear Family; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014019:Tissue Donors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000009:adverse effects